Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Bremelanotide (Vyleesi) vs Kisspeptin-10
An educational, source-based comparison of Bremelanotide (Vyleesi) and Kisspeptin-10 — how each peptide works, what it's researched for, and what to know before going deeper.
Melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women.
Cyclic 7-amino-acid synthetic analog of α-MSH that activates melanocortin receptors (primarily MC4R) in the CNS, modulating sexual desire pathways.
- Acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women
- • FDA-approved.
- • Nausea, flushing, transient BP elevation common.
A peptide product of the KISS1 gene that acts upstream of GnRH neurons via the KISS1R/GPR54 receptor. Research demonstrates robust LH (and indirectly testosterone/estradiol) responses without desensitizing the pituitary.
- Hypothalamic amenorrhea
- Male hypogonadism research
- IVF triggering protocols
- • Investigational; not FDA-approved.
- • Effects on the HPG axis warrant physician oversight.
Bremelanotide (Vyleesi) vs Kisspeptin-10 — Key differences
- Class: Bremelanotide (Vyleesi) is classified as Melanocortin Agonist · Sexual Health, while Kisspeptin-10 is Hormonal · HPG Axis.
- Primary research focus: Bremelanotide (Vyleesi) — acquired, generalized hypoactive sexual desire disorder (hsdd) in premenopausal women; Kisspeptin-10 — hypothalamic amenorrhea.
- Tag: FDA-Approved · Sexual Health vs Hormonal · HPG axis.